Solana price has held above key technical support even after slipping 1.7%, while U.S.-listed spot Solana ETFs have continued attracting fresh inflows as Bitcoin and Ethereum funds recorded weekly withdrawals.

After climbing more than 15% last week, Solana (SOL) price met selling pressure near the $80 level, where traders again defended resistance amid the broader market pullback. Even after the recent recovery, the token remains about 73% below its all-time high of $294.33 reached on Jan. 19, 2025.

Meanwhile, Bitcoin fell 1.65% during the same period, dragging the total cryptocurrency market capitalization down 1.47% to $2.14 trillion.

ETF demand has stayed positive despite market weakness

Fund flow data showed Solana diverging from the two largest cryptocurrencies during the latest reporting period. Spot Bitcoin ETFs recorded net outflows of $527 million between June 29 and July 2, extending their losing streak to eight consecutive weeks. Spot Ethereum ETFs also registered net outflows totaling $13.67 million.

By contrast, U.S.-listed spot Solana ETFs attracted $5.75 million in net inflows over the same period. The inflows indicated that investors continued adding exposure despite weakness across the wider digital asset market.

Capital also moved into several other altcoin investment products. XRP ETFs recorded $17.19 million in net inflows, while HYPE ETFs added another $4.32 million during the week.

Away from fund flows, on-chain activity continued to strengthen. According to SolanaFloor, Solana ranked second in global spot crypto trading volume for the second consecutive week, processing $12.25 billion across centralized and decentralized exchanges. That total remained ahead of Bybit’s $10.57 billion, although Binance retained the top position among exchanges during the reporting period.

SolanaFloor also reported that weekly non-vote transactions surpassed one billion for the first time. Unlike validator voting activity, non-vote transactions represent actual network usage generated by users, decentralized applications, and traders. The sharp rise at the beginning of July points to heavier activity across the ecosystem.

Technical structure still favors buyers above key support

Network participation has accelerated alongside the recovery. According to Artemis data, Solana’s weekly active addresses climbed from 16.8 million to 29.7 million in just two weeks, an increase of roughly 12.9 million wallets, or about 76.8%. The rebound followed slower activity during June as users returned to decentralized applications across the network.

Separate ecosystem rankings also kept Solana at the top of several blockchain activity metrics. The network led all Layer 1 and Layer 2 chains in both 24-hour and seven-day decentralized application revenue while also recording the highest decentralized exchange trading volume over those periods. Polygon, Ethereum, Base, BNB Chain and Hyperliquid followed behind across the tracked categories.

Price action continues to support the improving network data. On the daily chart, Solana remains above its 20-day, 50-day and 100-day moving averages, while the MACD indicator is still in bullish territory despite momentum easing after last week’s rally.

Advertisement

On the 4-hour chart, the Supertrend indicator continues to hold below price near $78.30, and Chaikin Money Flow has stayed slightly above zero, indicating modest buying pressure.

The latest consolidation has left immediate resistance around the recent high near $84, while the Supertrend level near $78 and the Fibonacci support around $76 remain the first areas buyers may need to defend if selling pressure returns. Together with steady ETF inflows and rising network activity, those technical levels suggest Solana’s recovery remains intact unless those support zones give way.

Disclosure: This article does not represent investment advice. The content and materials featured on this page are for educational purposes only.

Advertisement

Key Takeaways

• Rivian manufactured 12,613 vehicles and handed over 12,194 units in Q2 2026, surpassing its projection of 9,000–11,000 deliveries
• Full-year 2026 delivery expectations were increased to 65,000–70,000 vehicles from the previous 62,000–67,000 range
• Shares of RIVN climbed approximately 6% following the announcement, building on the prior week’s 10.2% increase
• Investment firm Baird maintained its Outperform rating with a $23 price objective, suggesting about 23% potential upside
• The quarterly performance benefited from EDV commercial van sales, R1 vehicle lineup, and initial R2 model shipments

Rivian (RIVN) is currently changing hands at $19.76, climbing roughly 6% on Monday, building momentum from the previous week’s 10.2% surge after the electric vehicle manufacturer reported quarterly delivery figures that substantially exceeded its own projections.

Rivian Automotive, Inc., RIVN

The automaker manufactured 12,613 units and completed deliveries of 12,194 vehicles throughout the three-month period concluded June 30. These numbers significantly outpaced Rivian’s internal projections of 9,000 to 11,000 deliveries.

Year-over-year delivery volume expanded by nearly 14%. The outperformance stemmed from robust demand for its electric commercial vans and R1 product line, combined with the commencement of R2 shipments — a development investors have been eagerly anticipating.

In response to these results, Rivian elevated its full-year 2026 delivery projections to a range of 65,000 to 70,000 vehicles. This represents an increase from the previous bracket of 62,000 to 67,000 — marking a 3,000-vehicle boost at the median point.

This represents an unusual positive development for a company whose public market history has been characterized more by missed projections than exceeded expectations.

Wall Street Analysts Express Support

Baird confirmed its Outperform rating and maintained its $23.00 price objective after reviewing the delivery data. With current trading levels between $18.63 and $19.76, this target suggests potential appreciation of approximately 23%.

Canaccord and Needham similarly reaffirmed Buy ratings, contributing to the favorable analyst sentiment surrounding the stock this week.

Baird’s projection had represented the most optimistic forecast among Wall Street firms, and Rivian’s actual delivery number fell marginally short of it — though still exceeded the broader consensus. The firm adjusted its financial model to incorporate the Q2 results while maintaining its rating.

One concern analysts highlighted: Rivian’s gross profit margin currently stands at merely 1%, which continues to represent a significant challenge despite improving production volumes.

R2 Introduction Provides Growth Narrative

The second quarter represented the beginning of R2 deliveries. Although volumes remain modest, production acceleration is anticipated throughout the latter half of 2026.

The R2 represents a more compact, affordably-priced vehicle targeting a wider consumer audience compared to the R1 trucks and SUVs. Rivian has characterized it as the product capable of achieving meaningful production scale.

Commercial van shipments through the EDV initiative also bolstered quarterly performance. This business segment has demonstrated consistent results, despite receiving less market attention than the consumer vehicle division.

Visible Alpha analysts forecast Rivian will achieve 63,138 total vehicle deliveries for the complete year — modestly under the midpoint of the revised guidance range, indicating some Wall Street observers maintain cautious expectations regarding production acceleration.

Looking Ahead

Rivian plans to release complete Q2 2026 financial results on July 30, following market closure. A live audio presentation is scheduled for 5:00 p.m. ET to discuss operational performance and forward outlook.

RIVN has gained 1.8% year-to-date but remains 12% beneath its 52-week peak of $22.45, established in December 2025.

Key Takeaways

• MRNA reached a 52-week peak of $81.42, representing a 169.2% annual increase
• Six-month performance shows a remarkable 124% climb
• InvestingPro identifies the stock as trading above its Fair Value calculation
• Wall Street analysts hold an average “Reduce” stance with a $37.13 mean target
• Corporate insiders have offloaded 125,088 shares totaling more than $6.1 million over 90 days

Moderna shares peaked at $81.42 on July 6, establishing a fresh 52-week record and continuing what has become one of biotech’s most dramatic rallies this year. Trading hovered around $81.51 shortly thereafter, pushing the company’s market capitalization to approximately $32.2 billion.

Moderna, Inc., MRNA

The 52-week floor stands at $22.28. This positions MRNA with more than a triple-digit gain from its nadir — specifically, a 169.2% total return over twelve months.

The half-year climb alone registers at 124%, fueled partly by revitalized enthusiasm for Moderna’s mRNA technology and multiple developmental announcements.

During its Science Day presentation, Moderna disclosed that mRNA-6007, its in vivo CAR-T initiative, is advancing into preliminary development targeting autoimmune conditions, particularly systemic lupus erythematosus and related B cell-driven disorders.

Regulatory developments also contributed momentum. An FDA advisory panel delivered a unanimous endorsement for Moderna’s experimental seasonal influenza vaccine, mRNA-1010, for the 50-and-over demographic — representing a significant validation for the company’s expanding portfolio.

Options market participants responded actively. Contract volume reached 121,257, with substantial interest concentrated in the June 18, 2026 $65 call option.

Wall Street Remains Unconvinced

Notwithstanding the share price momentum, the analyst consensus tells a starkly different story. Moderna holds an aggregate rating of “Reduce” with a consensus price objective of merely $37.13 — representing less than 50% of current trading levels.

Goldman Sachs elevated its projection from $43 to $49 while maintaining a “neutral” stance. Bank of America adjusted upward from $32 to $34 but preserved an “underperform” rating. Barclays increased from $25 to $48 with “equal weight.” Both Jefferies and UBS maintained “hold” recommendations.

Among analysts tracking MRNA, two assign it a Buy rating, eleven suggest Hold, and five recommend Sell.

InvestingPro analytics position the equity among the platform’s most overextended securities when measured against its Fair Value assessment.

Corporate Leadership Reduces Positions

While institutional investors have been accumulating shares, company insiders have been liquidating positions. Board member Abbas Hussain divested 5,682 shares at $46.63 on May 1, trimming his holdings by 32%. Board member Noubar Afeyan sold 9,263 shares at $46.84 on May 21, decreasing his position by 70.24%.

Cumulatively, corporate insiders have liquidated 125,088 shares valued at more than $6.1 million during the previous 90-day period. Insider ownership currently represents 10.80% of outstanding shares.

Regarding institutional activity, the trend appears more constructive. Louisiana State Employees Retirement System established a fresh position of 17,700 shares valued at approximately $899,000 during Q1. AQR Capital, NewEdge Advisors, and American Century Companies similarly expanded their holdings. Institutional ownership now accounts for 75.33% of MRNA.

The company’s latest quarterly disclosure, published May 1, revealed Q1 revenue of $389 million — representing a 260.2% year-over-year expansion and significantly exceeding the $236.37 million analyst estimate. Earnings per share registered at -$3.40, falling short of the consensus forecast of -$3.02. The stock’s 50-day moving average currently sits at $53.50, while its 200-day average rests at $48.22.

In 2025, OpenAI raised funding at a $300 billion valuation. That number didn’t come from a single product launch or a breakthrough sitting in a lab somewhere. It came from usage, hundreds of millions of people opening ChatGPT every day, asking it questions, writing code with it, drafting emails through it, editing documents, building entire workflows around it, for years on end. That accumulated usage is the actual asset behind the valuation. It’s what proved the product worked at scale, what justified the pricing, and what ultimately convinced investors the company was worth funding at that number. 

However, none of the people who generated that usage own any part of what it built. They paid a subscription, used the product, and walked away with nothing beyond the product itself. Stargate LLM is built around a different premise: that the people generating a platform’s usage should have a way to benefit from the value that usage creates, not just the company running it.

Where the $300 Billion Actually Came From

This isn’t a criticism of OpenAI’s business model so much as a description of how it works, and how every major AI platform’s valuation works. A company’s worth is built on engagement, retention, and the size of its active user base. ChatGPT’s usage numbers are the reason a $300 billion valuation was possible at all. Anthropic followed a similar trajectory, crossing $30 billion in annualized revenue in April 2026, again driven by daily usage from people using Claude for work, research, and everyday tasks.

The structure is consistent across the industry: users generate the data, the engagement, and the subscription revenue that make these companies valuable. The equity upside from that value sits with venture capital firms and early investors. The people doing the actual using never had an ownership stake to begin with, so there’s nothing for them to be paid out from.

Why This Structure Exists

This isn’t unique to AI. It’s how venture-backed software has worked for two decades. Google’s search engine ran on free usage from billions of people while a small group of early backers and employees became billionaires. The pattern repeats because private companies aren’t required to offer public equity, and by the time an IPO happens, if it happens at all, the earliest and steepest growth has usually already occurred. The users who built the company’s value in the meantime were never in a position to hold any of it.

AI has simply made this pattern more visible, because the scale is bigger and the growth is faster. A $300 billion valuation built substantially on usage is a bigger number than most historical examples, which is part of why it’s drawing more attention now than the same dynamic did with earlier tech platforms.

What Stargate LLM Does Differently

Stargate LLM is built around a different assumption: that usage itself should generate a return for the person doing the using, not just for the company running the platform. The mechanism for this is Proof of Usage, one of the largest allocations in Stargate’s tokenomics, with 50% of the total 150 billion coin supply, 75 billion Stargate coins, set aside specifically to reward users for real platform activity: conversational AI queries, image and video generation, referrals, staking, and structured feedback that improves the models.

This is a structural difference, not a marketing claim. The Stargate coin is required for core platform functions, subscriptions, credits, premium model access, which means usage and coin demand are directly connected from day one. Staking in the Stargate Vault adds a second layer: locked coins earn rewards drawn from platform revenue and the usage rewards pool, with governance votes determining how a portion of that revenue gets distributed to stakers over time. It means that the people generating the platform’s usage have a mechanism to benefit from that usage that ChatGPT and Claude’s user bases simply don’t have.

Stargate’s presale is where early access to this model is currently priced. It runs across ten escalating batches, from $0.0005 up to $0.0125, building toward a $0.025 launch price target, with Batch 1 entering at a 50x ratio to that target. Of the fixed 150 billion coin supply, 96% is allocated to community, ecosystem, and presale participants, with just 1% going to the core team, a deliberate contrast to the ownership concentration typical of venture-backed AI companies.

The Bottom Line

OpenAI’s $300 billion valuation and Anthropic’s $30 billion in revenue are both real, and both were built substantially on usage from people who hold no stake in either outcome. That’s not a flaw specific to those two companies; it’s how the current AI industry is structured almost everywhere, from Google to SpaceX to every major venture-backed platform before them. Stargate LLM’s bet is that a meaningful share of AI’s next phase of growth can be built differently, with usage rewarded directly rather than only benefiting the platform running it. The mechanism for that already exists in the tokenomics: Proof of Usage rewards, Vault staking, and governance-directed revenue distributions, all tied to the same coin users are already spending on the platform. The presale is where that structure starts, open to anyone with a wallet, not just the investors who got there first.

Explore Stargate LLM:

Website: Stargate.org

Buy: own.Stargate.com

Telegram: https://t.me/StargatellmOfficial

Twitter/X: https://x.com/Stargatellm

Disclaimer: This is a Press Release provided by a third party who is responsible for the content. Please conduct your own research before taking any action based on the content.